Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70

被引:45
作者
García-Echeverría, C [1 ]
机构
[1] Novartis Pharma AG, Oncol Res, CH-4002 Basel, Switzerland
关键词
D O I
10.2174/0929867013371905
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sre homology 2 (SH2) domains are protein modules that mediate intracellular protein-protein interactions in signal transduction pathways. The specific association of an SH2 domain with a phosphotyrosine-containing sequence of another protein induces a cascade of molecular interactions that effect a wide range of cellular processes. Alterations in these signaling pathways have been associated with the development and progression of a broad range of pathologies. Because of the regulatory role of SH2 domains in these signal transduction pathways, specific SH2 domains can be ideal targets for intervention with therapeutic agents in many different disease indications (e.g. cancer, osteoporosis, disorders of the immune and cardiovascular systems). Among the SH2 domains pursued as drug discovery targets in the last few years are those of Grb2, Src, Lck and ZAP-70. This review focuses on contributions in the design and synthesis of antagonists of these particular SH2 domains. Specific examples have been selected to illustrate how structure-based design approaches have been used to progress in this area of research.
引用
收藏
页码:1589 / 1604
页数:16
相关论文
共 125 条
[1]   The formation of a covalent complex between a dipeptide ligand and the src SH2 domain [J].
Alligood, KJ ;
Charifson, PS ;
Crosby, R ;
Consler, TG ;
Feldman, PL ;
Gampe, RT ;
Gilmer, TM ;
Jordan, SR ;
Milstead, MW ;
Mohr, C ;
Peel, MR ;
Rocque, W ;
Rodriguez, M ;
Rusnak, DW ;
Shewchuk, LM ;
Sternbach, DD .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (10) :1189-1194
[2]   Asterriquinones produced by Aspergillus candidus inhibit binding of the Grb-2 adapter to phosphorylated EGF receptor tyrosine kinase [J].
Alvi, KA ;
Pu, H ;
Luche, M ;
Rice, A ;
App, H ;
McMahon, G ;
Dare, H ;
Margolis, B .
JOURNAL OF ANTIBIOTICS, 1999, 52 (03) :215-223
[3]  
App H., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P349
[4]   Ligands for the tyrosine kinase p56lck SH2 domain:: Discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements [J].
Beaulieu, PL ;
Cameron, DR ;
Ferland, JM ;
Gauthier, J ;
Ghiro, E ;
Gillard, J ;
Gorys, V ;
Poirier, M ;
Rancourt, J ;
Wernic, D ;
Llinas-Brunet, M ;
Betageri, R ;
Cardozo, M ;
Hickey, ER ;
Ingraham, R ;
Jakes, S ;
Kabcenell, A ;
Kirrane, T ;
Lukas, S ;
Patel, U ;
Proudfoot, J ;
Sharma, R ;
Tong, L ;
Moss, N .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (10) :1757-1766
[5]   Correlation of the phosphorylation states of pp60(c-src) with tyrosine kinase activity: The intramolecular pY530-SH2 complex retains significant activity if Y419 is phosphorylated [J].
Boerner, RJ ;
Kassel, DB ;
Barker, SC ;
Ellis, B ;
DeLacy, P ;
Knight, WB .
BIOCHEMISTRY, 1996, 35 (29) :9519-9525
[6]  
Botfield M.C., 1995, ANN REP MED CHEM, V30, P227, DOI [10.1016/S0065-7743(08)60937-9, DOI 10.1016/S0065-7743(08)60937-9]
[7]   REQUIREMENT OF PP60C-SRC EXPRESSION FOR OSTEOCLASTS TO FORM RUFFLED BORDERS AND RESORB BONE IN MICE [J].
BOYCE, BF ;
YONEDA, T ;
LOWE, C ;
SORIANO, P ;
MUNDY, GR .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (04) :1622-1627
[8]   Structure-based design and synthesis of a novel class of Src SH2 inhibitors [J].
Buchanan, JL ;
Bohacek, RS ;
Luke, GP ;
Hatada, M ;
Lu, XD ;
Dalgarno, DC ;
Narula, SS ;
Yuan, R ;
Holt, DA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (16) :2353-2358
[9]   Structure-activity relationships of a novel class of Src SH2 inhibitors [J].
Buchanan, JL ;
Vu, CB ;
Merry, TJ ;
Corpuz, EG ;
Pradeepan, SG ;
Mani, UN ;
Yang, M ;
Plake, HR ;
Varkhedkar, VM ;
Lynch, BA ;
MacNeil, IA ;
Loiacono, KA ;
Tiong, CL ;
Holt, DA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (16) :2359-2364
[10]  
BUDAY L, 1994, J BIOL CHEM, V269, P9019